OMEROS CFO Executes Rapid Buy‑Sell Cycle, Balancing Gains Amid Strong Stock Momentum
OMEROS insider trades reveal disciplined buy‑sell strategy, not speculation—insights into VP David Borges’ moves and company growth prospects.
3 minutes to read
OMEROS CORP
OMEROS INSIDER TRADE SPARKS 55.9% SOCIAL-MEDIA BUZZ As Director Hanish Arnold C. Buys Low, Sells High, Hinting at a Range‑Bound Strategy and Potential Upside Restraint for the Biopharma Stock
Discover how insider trades by Hanish Arnold C. reveal Omeros’ valuation outlook and range‑bound strategy—insightful for investors eyeing biopharma growth.
4 minutes to read
OMEROS Insider Deals: Directors Buy Low, Sell High in Structured 10‑b5‑1 Play, Signaling Confidence Amid Rapid Stock Surge
Insider trades at OMEROS reveal disciplined buying‑selling strategy, boosting confidence in the company’s valuation and future prospects.
4 minutes to read
Cable Thomas J. Buys OMEROS Shares at $2.00 Amid Record Social‑Media Buzz and Sharp Market Rally
Insider buy: Cable Thomas J. snaps up 7,500 OMEROS shares at $2, buying at a discount amid 107% social‑media buzz—signal of confidence and potential upside.
3 minutes to read
Schocken’s No‑Cost Option Exercise Signals Long‑Term Confidence Amid Omeros’ Surge.
Omeros insider Schocken’s zero‑price option exercise signals long‑term confidence, amid a 310% YTD rally and potential future dilution, a bullish hint for investors.
3 minutes to read
Omeros Execs Trade Small but Strategic Moves, Bolstering Confidence in Growth Pipeline
Omeros insider trading shows CEO and finance VP buy‑sell moves, signaling confidence in its high‑growth specialty‑pharma pipeline and board strength.
3 minutes to read
CEO‑Level Buy‑Back: Omeros Chairman Greg Demopulos Buys 400,000 Shares, Betting on Breakthrough Pipeline and Share Rally
CEO‑level purchase of 400k Omeros shares signals confidence as the drug’s clinical momentum rises—what this means for investors.
3 minutes to read